{"count": 78, "results": [{"_id": "38299294", "pmid": 38299294, "title": "Advance of Metformin in Liver Disease.", "journal": "Curr Med Chem", "authors": ["Bao J", "Zhao Y", "Xu X", "Ling S"], "date": "2024-01-30T00:00:00Z", "doi": "10.2174/0109298673274268231215110330", "meta_date_publication": "2024 Jan 30", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50276.625, "text_hl": "Advance of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@Liver Disease@@@.", "citations": {"NLM": "Bao J, Zhao Y, Xu X, Ling S. Advance of Metformin in Liver Disease. Curr Med Chem. 2024 Jan 30;():. PMID: 38299294", "BibTeX": "@article{38299294, title={Advance of Metformin in Liver Disease.}, author={Bao J and Zhao Y and Xu X and Ling S}, journal={Curr Med Chem}}"}}, {"_id": "38192642", "pmid": 38192642, "pmcid": "PMC10773879", "title": "Metformin: update on mechanisms of action on liver diseases", "journal": "Front Nutr", "authors": ["Ruan G", "Wu F", "Shi D", "Sun H", "Wang F", "Xu C"], "date": "2023-12-14T00:00:00Z", "doi": "10.3389/fnut.2023.1327814", "meta_date_publication": "2023", "meta_volume": "10", "meta_issue": "", "meta_pages": "1327814", "score": 50276.586, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@: update on mechanisms of action on @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@liver diseases@@@", "citations": {"NLM": "Ruan G, Wu F, Shi D, Sun H, Wang F, Xu C. Metformin: update on mechanisms of action on liver diseases Front Nutr. 2023;10():1327814. PMID: 38192642", "BibTeX": "@article{38192642, title={Metformin: update on mechanisms of action on liver diseases}, author={Ruan G and Wu F and Shi D and Sun H and Wang F and Xu C}, journal={Front Nutr}, volume={10}, pages={1327814}}"}}, {"_id": "31960986", "pmid": 31960986, "title": "The safety and pharmacokinetics of metformin in patients with chronic liver disease.", "journal": "Aliment Pharmacol Ther", "authors": ["Smith FC", "Stocker SL", "Danta M", "Carland JE", "Kumar SS", "Liu Z", "Greenfield JR", "Braithwaite HE", "Cheng TS", "Graham GG", "Williams KM", "Day RO"], "date": "2020-03-01T00:00:00Z", "doi": "10.1111/apt.15635", "meta_date_publication": "2020 Mar", "meta_volume": "51", "meta_issue": "5", "meta_pages": "565-575", "score": 50266.63, "text_hl": "The safety and pharmacokinetics of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@chronic liver disease@@@.", "citations": {"NLM": "Smith FC, Stocker SL, Danta M, Carland JE, Kumar SS, Liu Z, Greenfield JR, Braithwaite HE, Cheng TS, Graham GG, Williams KM, Day RO. The safety and pharmacokinetics of metformin in patients with chronic liver disease. Aliment Pharmacol Ther. 2020 Mar;51(5):565-575. PMID: 31960986", "BibTeX": "@article{31960986, title={The safety and pharmacokinetics of metformin in patients with chronic liver disease.}, author={Smith FC and Stocker SL and Danta M and Carland JE and Kumar SS and Liu Z and Greenfield JR and Braithwaite HE and Cheng TS and Graham GG and Williams KM and Day RO}, journal={Aliment Pharmacol Ther}, volume={51}, number={5}, pages={565-575}}"}}, {"_id": "32425881", "pmid": 32425881, "pmcid": "PMC7212476", "title": "Metformin and Its Benefits for Various Diseases", "journal": "Front Endocrinol (Lausanne)", "authors": ["Lv Z", "Guo Y"], "date": "2020-04-16T00:00:00Z", "doi": "10.3389/fendo.2020.00191", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "191", "score": 50262.44, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@Liver Diseases@@@", "citations": {"NLM": "Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases Front Endocrinol (Lausanne). 2020;11():191. PMID: 32425881", "BibTeX": "@article{32425881, title={Metformin and Its Benefits for Various Diseases}, author={Lv Z and Guo Y}, journal={Front Endocrinol (Lausanne)}, volume={11}, pages={191}}"}}, {"_id": "40560437", "pmid": 40560437, "title": "The role of metformin in pediatric metabolic dysfunction-associated steatotic liver disease.", "journal": "Eur J Pediatr", "authors": ["Gkiourtzis N", "Michou P", "Fotoulaki M"], "date": "2025-06-25T00:00:00Z", "doi": "10.1007/s00431-025-06288-1", "meta_date_publication": "2025 Jun 25", "meta_volume": "184", "meta_issue": "7", "meta_pages": "444", "score": 50260.5, "text_hl": "The role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in pediatric @DISEASE_Metabolic_Diseases @DISEASE_MESH:D008659 @@@metabolic dysfunction@@@-associated @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@steatotic liver disease@@@.", "citations": {"NLM": "Gkiourtzis N, Michou P, Fotoulaki M. The role of metformin in pediatric metabolic dysfunction-associated steatotic liver disease. Eur J Pediatr. 2025 Jun 25;184(7):444. PMID: 40560437", "BibTeX": "@article{40560437, title={The role of metformin in pediatric metabolic dysfunction-associated steatotic liver disease.}, author={Gkiourtzis N and Michou P and Fotoulaki M}, journal={Eur J Pediatr}, volume={184}, number={7}, pages={444}}"}}, {"_id": "38049180", "pmid": 38049180, "pmcid": "PMC10786205", "title": "Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "journal": "J Obes Metab Syndr", "authors": ["Shin S", "Kim J", "Lee JY", "Kim J", "Oh CM"], "date": "2023-12-05T00:00:00Z", "doi": "10.7570/jomes23054", "meta_date_publication": "2023 Dec 5", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50258.395, "text_hl": "In several clinical trials, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been shown to have beneficial effects on @DISEASE_Fatty_Liver @DISEASE_MESH:D005234 @@@fatty liver disease@@@, despite the controversy in the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@MASLD@@@ found in the meta-analysis of randomized controlled trials. ", "citations": {"NLM": "Shin S, Kim J, Lee JY, Kim J, Oh CM. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) J Obes Metab Syndr. 2023 Dec 5;():. PMID: 38049180", "BibTeX": "@article{38049180, title={Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)}, author={Shin S and Kim J and Lee JY and Kim J and Oh CM}, journal={J Obes Metab Syndr}}"}}, {"_id": "40120569", "pmid": 40120569, "title": "Impact of metformin on HBV replication: No evidence of suppression in vitro.", "journal": "J Clin Virol", "authors": ["Hawkins C", "Waddilove E", "Matthews PC", "Delphin M"], "date": "2025-03-17T00:00:00Z", "doi": "10.1016/j.jcv.2025.105781", "meta_date_publication": "2025 Mar 17", "meta_volume": "177", "meta_issue": "", "meta_pages": "105781", "score": 50257.832, "text_hl": "CONCLUSIONS: In @CELLLINE_CVCL:M177 @@@HepAD38@@@ cells, @SPECIES_10407 @@@HBV@@@ replication is not impacted by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment. This contrasts with prior in vitro data but is in line with clinical evidence that suggests @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ acts through an influence on @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@liver disease@@@ progression rather than a direct antiviral impact on @SPECIES_10407 @@@HBV@@@ itself.", "citations": {"NLM": "Hawkins C, Waddilove E, Matthews PC, Delphin M. Impact of metformin on HBV replication: No evidence of suppression in vitro. J Clin Virol. 2025 Mar 17;177():105781. PMID: 40120569", "BibTeX": "@article{40120569, title={Impact of metformin on HBV replication: No evidence of suppression in vitro.}, author={Hawkins C and Waddilove E and Matthews PC and Delphin M}, journal={J Clin Virol}, volume={177}, pages={105781}}"}}, {"_id": "40466424", "pmid": 40466424, "title": "[The role of metformin in the cardiokidney-metabolic patient].", "journal": "Semergen", "authors": ["Arranz Martínez E", "Hernández-Teixidó C", "Ruíz García A"], "date": "2025-06-03T00:00:00Z", "doi": "10.1016/j.semerg.2025.102530", "meta_date_publication": "2025 Jun 3", "meta_volume": "51", "meta_issue": "7", "meta_pages": "102530", "score": 50255.53, "text_hl": "[The role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in the cardiokidney-metabolic @SPECIES_9606 @@@patient@@@].", "citations": {"NLM": "Arranz Martínez E, Hernández-Teixidó C, Ruíz García A. [The role of metformin in the cardiokidney-metabolic patient]. Semergen. 2025 Jun 3;51(7):102530. PMID: 40466424", "BibTeX": "@article{40466424, title={[The role of metformin in the cardiokidney-metabolic patient].}, author={Arranz Martínez E and Hernández-Teixidó C and Ruíz García A}, journal={Semergen}, volume={51}, number={7}, pages={102530}}"}}, {"_id": "35419709", "pmid": 35419709, "pmcid": "PMC9007580", "title": "The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases", "journal": "Inflammopharmacology", "authors": ["Hasanvand A"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s10787-022-00980-6", "meta_date_publication": "2022 Jun", "meta_volume": "30", "meta_issue": "3", "meta_pages": "775-788", "score": 50253.44, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and therapeutic goals", "citations": {"NLM": "Hasanvand A. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases Inflammopharmacology. 2022 Jun;30(3):775-788. PMID: 35419709", "BibTeX": "@article{35419709, title={The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases}, author={Hasanvand A}, journal={Inflammopharmacology}, volume={30}, number={3}, pages={775-788}}"}}, {"_id": "37664227", "pmid": 37664227, "pmcid": "PMC10433257", "title": "Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus", "journal": "Ann Gastroenterol", "authors": ["Huynh DJ", "Renelus BD", "Jamorabo DS"], "date": "2023-09-01T00:00:00Z", "doi": "10.20524/aog.2023.0814", "meta_date_publication": "2023 Sep-Oct", "meta_volume": "36", "meta_issue": "5", "meta_pages": "555-563", "score": 50250.656, "text_hl": "Dual @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and glucagon-like peptide-1 receptor agonist therapy reduces mortality and @<m>DISEASE_Liver_Diseases</m> @DISEASE_MESH:D008107 @@@hepatic complications@@@ in @DISEASE_Idiopathic_Noncirrhotic_Portal_Hypertension @DISEASE_MESH:D000094724 @@@cirrhotic@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@", "citations": {"NLM": "Huynh DJ, Renelus BD, Jamorabo DS. Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus Ann Gastroenterol. 2023 Sep-Oct;36(5):555-563. PMID: 37664227", "BibTeX": "@article{37664227, title={Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus}, author={Huynh DJ and Renelus BD and Jamorabo DS}, journal={Ann Gastroenterol}, volume={36}, number={5}, pages={555-563}}"}}]}